A special kind of genetic test that helps determine the best antidepressant for patients with moderate-to-severe depression could generate substantive health system savings and greatly improve patient outcomes, according to new research from the University of British Columbia. The study, published today in CMAJ, shows that in B.C. alone, implementing pharmacogenomic testing could save...